Munn S, Chu A C
Imperial College School of Medicine, London, United Kingdom.
Hematol Oncol Clin North Am. 1998 Apr;12(2):269-86. doi: 10.1016/s0889-8588(05)70510-4.
Cutaneous involvement in Langerhans cell histiocytosis (LCH) occurs in 50% of cases and may be the presenting feature. It is, therefore, important to recognize the wide spectrum of clinical disease that this disorder may adopt in the skin. Cutaneous involvement is not necessarily a benign feature and many patients progress to multi-system disease. There are a number of treatments available for cutaneous LCH. The rationale is to start with the simplest treatment and progress to systemic or interventional therapy as needed.
